

業績目録(令和6年)

大学院科目名：呼吸器内科学

(A-a) 英文著書

なし

(A-b) 和文著書

1. 合田 志穂, 辻 泰佑, 山本 航平, 笹倉 美咲, 田中 駿也, 塩津 伸介, 弓場達也, 内匠 千恵子, 平岡 範也
当院における気管支肺胞洗浄での鎮静薬使用の有無による気管支肺胞洗浄液の回収率に関する後方視的検討
気管支学 46 巻1号 p13-19 2024

(B-a) 英文総説

1. Fukuda A, Okuma Y
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res 1;30(15):3128-3136. 2024

(B-b) 和文総説

1. 山田 忠明, 高山 浩一
非小細胞肺癌(初期)
非小細胞肺癌(初期) エルゼビア・ジャパン 2024
2. 立花 佑介, 高山 浩一
【がんと全身性代謝変容 がん悪液質を再定義し、代謝・免疫の変調への早期介入をめざす】がん悪液質治療の最前線
実験医学 羊土社
42(4), 547-551, 2024
3. 立花 佑介, 高山 浩一
【悪液質と栄養】がん悪液質と薬物療法
栄養 ジェフコーポレーション
39(1), 17-23, 2024

4. 福泉 彩, 赤松弘朗, 朝倉啓介, 小暮啓人, 榊原里江, 新納英樹, 山田忠明, 佐々木高明, 竹中朋祐, 田中謙太郎, 田中雄悟, 野津田泰嗣, 秦 明登, 福井麻里子, 古本秀行, 土田正則

2023 年度 日本肺癌学会会員におけるアーリーキャリアに関するアンケート調査結果

肺癌 64(3), 151-157 2024

5. 藤井博之, 角南久仁子

がんゲノム医療

日本医師会雑誌 日本医師会

第 153 巻・特別号(2), 2024

(C-a) 英文原著

1. Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y, Takei S, Kawachi H, Nakanishi K, Yamanaka Y, Tamiya N, Honda R, Okura N, Yamada T, Uryu K, Murai J, Shiotsu S, Yoshioka H, Yamada T, Kurata T, Takayama K.

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression $\leq 49\%$: a multicenter retrospective study. Front Oncol. 14:1303543. 2024 (IF: 3.3)

2. Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Iwasaku M, Tokuda S, Tanaka N, Miyagawa-Hayashino A, Takayama K.

Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study. JTO Clin Res Rep. 5(3):100644. 2024 (IF: 3.5)

3. Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, Yamaguchi K, Moriguchi M, Sogame Y, Yasuda H, Iwasaku M, Konishi H, Takayama K, Itoh Y.

Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database of Japan.

Gastroenterol. 59(2):145–156. 2024 (IF: 5.5)

4. *Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, Nakamura R, Morimoto K, Horinaka M, Sakai T, Sekido Y, Tokuda S, Takayama K.
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Mol Cancer Ther. 23(2):212–222. 2024 (IF: 5.5)

5. Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS $\geq$ 50.

Front Immunol. 15:1348034. 2024 (IF: 5.9)

6. Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

JAMA Oncol. 10(3):315–324. 2024 (IF: 20.1)

7. Shimizu D, Ishibashi M, Yamada T, Toda Y, Hosogi S, Ashihara E.

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.

Cancer Genomics Proteomics. 21(2):158–165. 2024 (IF: 2.6)

8. *Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K.

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

Cancer Lett. 587:216692.2024 (IF: 10.1)

9. Yamamoto C, Taniguchi M, Furukawa K, Inaba T, Niiyama Y, Ide D, Mizutani S, Kuroda J, Tanino Y, Nishioka K, Watanabe Y, Takayama K, Nakaya T, Nukui Y

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.

Viruses16(5):718.2024 (IF: 3.5)

10. Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis:a propensity-matched real-world analysis.

J Cancer Res Clin Oncol 150(4):216.2024 (IF: 3.5)

11. Takayama K, Kojima A, Honda C, Nakayama M, Kanemata S, Endo T, Muro K.

Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.

Cancer Med. 13(9):e7170.2024 (IF: 3.1)

12. Katayama Y, Yamada T, Sawada R, Kawachi H, Morimoto K, Watanabe S, Watanabe K, Takeda T, Chihara Y, Shiotsu S, Hibino M, Harada T, Nishioka N, Iwasaku M, Tokuda S, Takayama K.

Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.

Oncologist. 29(5):e681-e689.2024 (IF: 4.2)

13. Ishida M, Iwasaku M, Doi T, Ishikawa T, Tachibana Y, Sawada R, Ogura Y, Kawachi H, Katayama Y, Nishioka N, Morimoto K, Tokuda S, Yamada T, Takayama K.

Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.

Cancer Sci. 115(5):1656-1664. 2024 (IF: 4.3)

14. Onoi K, Yamada T, Morimoto K, Kawachi H, Tsutsumi R, Takeda T, Okada A, Tamiya N, Chihara Y, Shiotsu S, Takemura Y, Yamada T, Hasegawa I, Katayama Y, Iwasaku M, Tokuda S, Takayama K.

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.

Target Oncol. 19(3):411-421. 2024 (IF: 4.0)

15. Okuma Y, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H.

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.

Clin Lung Cancer. 25(4):336-346. 2024 (IF: 3.3)

16. Yamamoto C, Nukui Y, Furukawa K, Taniguchi M, Yamano T, Inaba T, Kikai R, Tanino Y, Yamada Y, Teramukai S, Takayama K.

SARS-CoV-2 RT-PCR as a universal screening on planned admission in asymptomatic patients.

J Infect Chemother 30(7):668-671. 2024 (IF: 1.5)

17. Kanbayashi Y, Ishikawa T, Otsuji E, Takayama K.

Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis.

Oncology. 102(7):604-610. 2024 (IF: 1.8)

18. Takayama K.

Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia.

Future Oncol. 13:1-11. 2024 (IF: 2.6)

19. *Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T, Takayama K, Sakai T.
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
Br J Cancer. 131(2):361-371. 2024 (IF 6.8)
20. Nishioka N, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Masui T, Sai N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Front Immunol. 15:1399889. 2024 (IF: 5.9)
21. Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K.
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Clin Lung Cancer. S1525-7304(24)00152-9. 2024 (IF: 3.3)
22. Takayama K, Furuse J, Muro K.
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with gastrointestinal cancer and cachexia.
Future Oncol. 12:1-10. 2024 (IF: 2.6)
23. *Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an

FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.

Cancer Lett. 598:217124. 2024 (IF: 10.1)

24. Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K.

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

Invest New Drugs. 42(5):538–546. 2024 (IF: 2.7)

25. Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Nishioka N, Iwasaku M, Tokuda S, Takayama K.

CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.

Transl Lung Cancer Res. 13(8):1929–1937. 2024 (IF: 3.5)

26. Kuno H, Nishioka N, Yamada T, Kunitatsu Y, Yoshimura A, Hirai S, Futamura S, Masui T, Egami M, Chihara Y, Takayama K.

The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.

Cancers (Basel). 16(17):3037. 2024 (IF: 4.4)

27. Morimoto K, Hamashima R, Yamada T, Yokoyama T, Kobayashi T, Tsuyuguchi K, Kanematsu T, Tamiya N, Tsuji T, Nakamura R, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Takayama K.

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.

Thorac Cancer. 15(26):1882–1888. 2024 (IF: 2.3)

28. Sakakida, T, Ishikawa, T, Doi, T, Morita, R, Kataoka, S, Miyake, H, Yamaguchi, K., Moriguchi, M, Sogame, Y, Yasuda, H, Iwasaku, M, Konishi, H, Takayama, K & Itoh Y.
Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
J Gastroenterol. 59(2):145-156.2024 (IF: 5.5)
29. *Matsui, Y, Yamada, T, Katayama, Y, Hirai, S, Sawada, R, Tachibana, Y, Ishida, M, Kawachi, H, Nakamura, R , Nishioka, N, Morimoto, K, Iwasaku, M, Horinaka, M, Sakai, T, Tokuda, S, Takayama, K.
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
Cancer Sci.115(10):3333-3345.2024 (IF: 4.3)
30. Doi T, Ishikawa T, Sakakida T, Itani J, Sone D, Morita R, Kataoka S, Miyake H, Seko Y , Yamaguchi K, Moriguchi M, Sogame Y, Konishi H, Murashima K, Iwasaku M, Takayama K, Itoh Y.
Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.
Cancer Sci. 115(11):3729-3739.2024 (IF: 4.3)
31. Fujii H, Hirano H, Shiraishi K, Shoji H, Hirose T, Okita N, Takashima A, Koyama T, Kato K.
Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database.
JCO Precis Oncol. 8:e2400284.2024 (IF: 5.6)
32. Takahashi Y, Shimazu Y, Shindo K, Fukui M, Chihara Y, Miyoshi T, Imashuku S.
Acquired Factor V Inhibitor Developed after Radio-chemotherapy for Non-small Cell Lung Carcinoma.
Oncology Advances 2024 vol. 2(1) 55-57 2024

(C-c) 和文原著

なし

(D) 学会発表

I) 招待講演、特別講演、教育講演等

1. 高山浩一

進行期肺がんの薬物療法

第 76 回日本内科学会九州支部生涯教育講演会 2024 年 1 月 福岡

2. 高山浩一

がん悪液質ケアのナビゲート～疫学から治療薬まで～

第 39 回日本臨床栄養代謝学会学術集会 2024 年 1 月 神奈川

3. 高山浩一

がん悪液質の包括的治療

第 61 回日本外科代謝栄養学会 2024 年 7 月 大阪

II) シンポジウム、ワークショップ、パネルディスカッション等

1. 山田 忠明

がん分子標的薬抵抗性を標的とした治療法開発

第 21 回日本臨床腫瘍学会学術集会 2024 年 2 月 愛知

2. 片山勇輝、山田忠明、高山浩一

ドライバー遺伝子異常肺がんにおける治療抵抗性機構の解明と治療法開発

第 64 回日本呼吸器学会総会 2024 年 4 月 東京

3. 中邨亮太、山田忠明、片山勇輝、西岡直哉、森本健司、岩破将博、徳田深作、康廣とも子、小崎龍平、高山浩一

EGFR 遺伝子変異陽性肺がんの根治を目指した初期併用療法に関する基礎的検討

第 64 回日本呼吸器学会総会 2024 年 4 月 東京

4. 片山勇輝、澤田凌、森本健司、山田忠明

非小細胞肺がんにおける複合免疫療法後のドセタキセル、ラムシルマブ併用療法の検討：多施設共同前向き観察研究

第 28 回日本がん分子標的治療学会学術集会 2024 年 6 月 東京

5. 中邨亮太、康廣とも子、小崎龍平、山田忠明

EGFR 変異陽性肺がんにおける Osimertinib+ONO-7475 初期併用治療の抵抗性機構解明と克服法開発

第 28 回日本がん分子標的治療学会学術集会 2024 年 6 月 20 東京

6. 山田忠明、松井遥平

EGFR 変異陽性肺がんにおける Lazertinib 初期抵抗性の克服を目指した基礎的検討

第 28 回日本がん分子標的治療学会学術集会 2024 年 6 月 東京

7. 森本健司、平井聡一、片山勇輝、堀中真野、酒井敏行、矢野聖二、山田忠明

KRAS-G12C 遺伝子変異陽性非小細胞肺がんにおける AXL シグナル活性化を介した初期治療抵抗性機構の解明

第 28 回日本がん分子標的治療学会学術集会 2024 年 6 月 東京

8. 吉村 彰紘、堀中 真野、山田 忠明、酒井 敏行

KRAS 変異陽性肺がんにおける新規 RAF/MEK 阻害薬と FAK 阻害薬併用治療の有効性についての検討

第 28 回日本がん分子標的治療学会学術集木会 2024 年 6 月 東京

III) 国際学会における一般発表

1. AACR Annual Meeting 2024(In San Diego, California)

Morimoto K, Yamada T, Hirai S, Katayama Y, Kunimasa K, Sasaki T, Nishida M, Watanabe S, Shiotsu S, Uehara H, Takayama K.

AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer.

2. Sawada R, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Kijima T, Takayama K.

Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPS.

3. Kawachi H, Takei S, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Kijima T, Takayama K.
Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expression.
4. Yamada T, Matsui Y, Takayama K.
Targeting AXL and MCL-1 to eradicate Lazertinib tolerance in EGFR-mutated NSCLC cells.
5. ASCO 2024 Annual Meeting(In Chicago, USA)
Kogure Y, Hashimoto H, Daga H, Fukuda Y, Bessho A, Yamada T, Toi Y, Kimura T, Yoshioka H, Azuma K, Furuya N, Fukui Y, Saka H, Kondo M.
Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.
6. Saida Y, Asao T, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, Ishikawa N, Yamada T, Tanaka T, Morita S, Kikuchi T, Maemondo M, Kobayashi K.
Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).
7. Fujii H, Syoji H, Hirano H, Hirose T, Okita N, Takashima A, Kato K.
Protein expression of Claudin 18.2, Nectin-4, HER-3, and PD-L1 in small bowel adenocarcinoma: Exploring potential targets of antibody drugs.

8. ESMO Congress 2024(In Barcelona, Spain)

Katayama Y, Yamada T, Sawada R, Harada T, Chihara Y, Yoshimura A, Shiotsu S, Okada A, Yamada T, Takemura Y, Takayama K.

The Impact of Gut Microbiome on the Efficacy of Ipilimumab and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer: A Prospective Observational Study.

E 研究助成（競争的研究助成金）

総額 580 万円（全ての小計の合計）

公的助成

代表 小計 330 万円

1. 文部科学省科学研究費 基盤 C 令和 5 年度～令和 7 年度
肺がん低酸素環境適応機構に起因した治療抵抗性の解明と新規標的治療法開発
山田忠明（代表）助成金額 90 万円
2. 文部科学省科学研究費 若手研究 令和 5 年度～令和 7 年度
新たな視点で肺がん患者の療養実態に迫り、医療の課題を解明する研究
岩破將博（代表）助成金額 170 万円
3. 文部科学省科学研究費 若手研究 令和 5 年度～令和 7 年度
Steven-Johnson 症候群の慢性期粘膜障害に関わる好中球機能の検討
金子美子（代表）助成金額 70 万円

財団等からの助成

代表（総額） 250 万円

1. 公益財団法人公益推進協会
ENT M Dr. 浅野登&暉子基金医学基礎研究助成事業
片山勇輝（代表）助成金額 50 万円
2. 公益財団法人 SGH 財団
第 36 回 SGH がん研究助成金
片山勇輝（代表）助成金額 200 万円